Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7)

Type2 Diabetes Clinical Trial

— GB7  

Official title:

Brown Fat Energy Metabolism During Cold Exposure: Effects of Fructose- or Glucose-rich Diet in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03188835
• Other study ID #: 2017-1459
• Status: Completed
• Phase: N/A
• Start date: May 23, 2017
• Est. completion date: April 30, 2021

Study information

• Verified date: May 2022
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Activating brown and beige adipose tissue (herein described as BAT) has been recently recognized as a potential means to increase energy expenditure and lower blood glucose, however, BAT activity appears to be reduced with obesity, aging or Type 2 Diabetes (T2D). BAT has the unique capability to burn large amounts of sugar and fat and effectively dissipate this energy as heat due to the expression of uncoupling protein 1 (UCP1) which is controlled by a thermogenic gene program of transcription factors, co-activators and protein kinases. Thus, enhancing the thermogenic gene program may be beneficial for treating obesity and T2D. Despite the importance of BAT in regulating metabolism our understanding of the factors which suppress its metabolic activity with obesity, aging and T2D are largely unknown. Recently, it was shown that peripheral serotonin, which is regulated by the tryptophan hydroxylase 1 (Tph1), is a negative regulator of BAT metabolic activity. In addition to serotonin, other studies have indicated that pro-inflammatory stimuli may also inhibit BAT metabolic activity. These data suggest that reduced activation of BAT may be due to increases in peripheral serotonin and inflammation. Importantly, the gut microbiome has recently been recognized as an important regulator of serotonin and inflammatory pathways suggesting the observed effects of the microbiome on obesity, T2D may be mediated in part through reductions in BAT activity.

One mechanism by which the environment may impact BAT activity and the thermogenic gene program over the last 3 decades involves changes in our food supply as result of changes in agricultural production (chlorpyrifos, glyphosphate) and the addition of food additives (fructose). These agents have been reported to alter inflammation, serotonin metabolism and the gut microbiome indicating a potential bimodal (direct and indirect via the microbiome) mechanism by which they may alter the thermogenic gene program and contribute to chronic metabolic disease. Thus, our overarching hypothesis is that environmental agents and additives related to food production may contribute to the reduced metabolic activity of BAT. The objective is to identify and characterize how food production agents and additives reduce the metabolic activity of BAT.

Description:

Each subject will follow 3 metabolic studies (A, B and C), each lasting 7.5h which includes a 3h acute cold exposure.

These studies will be almost identical: same perfusion of tracers, same number of Positron Emission Tomography (PET) acquisitions and same number of Magnetic Resonance Imaging (MRI) associated with Magnetic Resonance Spectroscopy (MRS) acquisitions .

The difference will be in the diet ingested by the subjects two weeks before each metabolic study: during protocol A, the subjects will follow an isocaloric diet; during protocol B, the subjects will follow the same isocaloric diet supplemented with a daily beverage containing +25% of energy intake from fructose; and during protocol C, the subjects will follow the same isocaloric diet supplemented with a daily beverage containing +25% of energy intake from glucose.

Stool samples will be collected for each metabolic study for microbiome flora and metabolites.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: April 30, 2021
• Est. primary completion date: December 17, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 35 Years

Eligibility

Inclusion Criteria:

• Healthy subjects: subjects with normal glucose tolerance determined according to an oral glucose tolerance test and with a BMI < 27 kg/m2 without first degree of familial history of type 2 diabetes (parents, siblings).

Exclusion Criteria:

1. Plasma triglycerides > 5.0 mmol/L at fasting;

2. More than 2 alcohol consumption per day;

3. More than 1 cigarette per day;

4. History of total cholesterol level > 7 mmol/L, of cardiovascular disease, hypertensive crisis;

5. Treatment with fibrates, thiazolidinedione, insulin, beta-blockers or other drugs with effects on insulin resistance or lipid metabolism (exception for anti-hypertensive drugs, statins or metformin);

6. Presence of a non-controlled thyroid disease, renal or hepatic disease, history of pancreatitis, bleeding diatheses, cardiovascular disease or any other serious medical conditions;

7. History of serious gastrointestinal disorders (malabsorption, peptic ulcer, gastroesophageal reflux having required a surgery, etc.);

8. Presence of a pacemaker;

9. Have undergone of PET study or CT scan in the past year;

10. Chronic administration of any medication;

Related Conditions & MeSH terms

• Type2 Diabetes

Intervention

Dietary Supplement:
• Diet
A 2 weeks of hypercaloric diet supplemented with fructose or glucose

Other:
• cold exposure
Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.

Radiation:
• 18FDG
I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
• 11C-acetate
i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
• [3-3H]-glucose
i.v. administration of 1.5 uCi/min of [3-3H]-glucose

Other:
• [U-13C]-palmitate
i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
• 2H-Glycerol
i.v. administration of 0.05 µmol/kg/min of 2H-glycerol

Device:
• MRI/MRS
Visceral and cervico-thoracic MRI and MRS acquisition.
• Electromyogram (EMG)
Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
• DXA
Lean mass will be determined by dual-energy X-ray absorptiometry
• Indirect calorimetry
VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.

Locations

Country	Name	City	State
Canada	Centre de recherche du CHUS	Sherbrooke	Quebec

Sponsors (3)

Lead Sponsor	Collaborator
Université de Sherbrooke	McMaster University, University of Ottawa

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Microbiome flora	assessed from stool samples	4 months
Primary	Microbiome metabolites	assessed from stool samples	4 months
Primary	BAT oxidative metabolism	will be determined using i.v. injection of 11C-acetate during dynamic PET/CT scanning	4 months
Primary	BAT triglyceride content	will be determined by radiodensity or MRS	4 months
Secondary	BAT blood flow	will be determined using i.v. injection of 11C-acetate during dynamic PET/CT scanning	4 months
Secondary	BAT net glucose uptake	will be assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning.	4 months
Secondary	Whole-body glucose partitioning	will be assessed using i.v. injection of 18FDG with static PET/CT scanning	4 months
Secondary	BAT volume of metabolic activity	will be determined using a total body CT (16 mA) followed by a PET acquisition	4 months
Secondary	metabolites appearance rate	will be determined by perfusion of stable isotope tracers	12 months
Secondary	energy metabolism (whole body production)	by indirect calorimetry	4 months
Secondary	hormonal responses	analysed by colorimetric and Elisa tests	12 months